Regulatory Exclusivity Expiring in 2028
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Drugs with Regulatory Exclusivity Expiring in 2028
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Exclusivity Expiration | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-001 | Jun 10, 2021 | RX | Yes | No | See Plans and Pricing | PEDIATRIC EXCLUSIVITY | |
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | PELLETS;ORAL | 214187-002 | Jun 10, 2021 | RX | Yes | Yes | See Plans and Pricing | PEDIATRIC EXCLUSIVITY | |
Abbvie Inc | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | See Plans and Pricing | PEDIATRIC EXCLUSIVITY | |
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-002 | Mar 19, 2020 | RX | Yes | No | See Plans and Pricing | PEDIATRIC EXCLUSIVITY | |
Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | See Plans and Pricing | PEDIATRIC EXCLUSIVITY | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Exclusivity Expiration | >Patented / Exclusive Use |